GEPAR-TRIO
Changing chemotherapy regimens midstream on the basis of individual patient responses to the first 2 cycles pays off with improved overall survival (OS) and disease-free survival (DFS) rates for patients with luminal-type breast cancers, according to a study reported here at the 34th Annual San Antonio Breast Cancer Symposium (SABCS).
But patients with HER2-positive or triple-negative (lacking HER2, estrogen, and progesterone receptors) tumors did not have a benefit from response-guided therapy, reported Gunther von Minckwitz, MD, PhD, professor and senior physician at the Center for Gynecology and Obstetrics at the University of Frankfurt in Frankfurt, Germany, on behalf of colleagues in the GEPAR-TRIO (GErman Pre-operative Adriamycin and Docetaxel) trial.
The trial also showed a disconnect between treatment effects and complete responses on pathology (pCR) in some disease subtypes,.......
Žádné komentáře:
Okomentovat
Poznámka: Komentáře mohou přidávat pouze členové tohoto blogu.